Hemgenix has been supplied ‘conditional authorisation’. Which means that the European Medicines Company decided that the advantages of Hemgenix are bigger than its risks, but the organization must deliver more evidence right after authorisation.Specialists pointed out that the amount of people expected to obtain etranacogene dezaparvovec in ano